HCMI was created and funded by the National Cancer Institute, Cancer Research UK, foundation Hubrecht Organoid Technology, and Wellcome Trust Sanger Institute. Together, these organizations develop policy and make programmatic decisions to contribute to the function of the HCMI.
The National Cancer Institute’s (NCI) Office of Cancer Genomics (OCG), within the Center for Cancer Genomics (CCG) manages the Cancer Model Development Centers (CMDCs). OCG also helps to facilitate communication between the CMDCs and the model development teams from CRUK, the HUB, and WTSI.
Cancer Research UK (CRUK) and Wellcome Trust Sanger Institute (WTSI) are co-funding organoid generation for the United Kingdom’s arm of HCMI. CRUK have leveraged their unique network of clinical sites to access clinical samples and WTSI will derive and sequence organoid models.
The foundation Hubrecht Organoid Technology (HUB) is a not-for-profit organization founded by the Royal Netherlands Academy of Sciences and the University Medical Center Utrecht. The HUB will generate and sequence organoid models for HCMI.
This group shares knowledge and protocols to advance and refine model development. Though the data collection mechanisms for each of these groups will not be identical, every effort will be made to maintain uniformity. The models will be made available through a single distributor, ATCC.
The governance group of the funders has been established in order to ensure the coordination of all efforts within the HCMI. The roles of the governance group include defining standard principles and methodologies as they relate to aspects of patient consent and clinical data collection, intellectual property, molecular analysis, and clinical data dissemination; establishing a model distribution mechanism; setting timelines for deliverables; ensuring communication amongst the consortium; and advertising the successes of the program via publication of peer-reviewed manuscripts and press releases.
ATCC is a non-profit biorepository whose mission within the HCMI will be to (1) acquire cancer models from the generating laboratories, (2) authenticate and preserve the models and evaluate them for quality, and (3) globally distribute the models and supportive information.